Citations

Clear

634 citation(s) found for "Hall, A".

Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
Bajorek, Lynn, Kiekhofer, Rachel, Hall, Matthew J. , Taylor, Joanne, Lucente, Diane , Brushaber, Danielle , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Forsberg, Leah K. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan, Grant, Ian , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Toga, Arthur W. , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Hall, Matthew, Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.050692 Get It

AbstractBackgroundUp to 30% of frontotemporal dementia (FTD) cases are due to known pathogenic mutations (f‐FTD). Little is known about the factors that predict who will choose to learn their results. Upcoming clinical trials in f‐FTD may require disclosure prior to enrollment, even before symptom onset, and thus characterizing this sample is important. Furthermore, understanding the mood impacts of genetic disclosure may guide genetic counseling practice.MethodF‐FTD participants (n=568) from families with a known pathogenic mutation (MAPT, C9orf72, GRN) were enrolled through the ARTFL/LEFFTDS Longitudinal FTD Study (ALLFTD) and provided the opportunity for disclosure. Independent‐sample t‐tests compared demographic and psychosocial factors between participants who did and did not receive their results. In participants who were asymptomatic at baseline and follow up (n=199,177 with follow‐up), linear mixed effects modeling was used to investigate pre‐ to post‐disclosure changes in the 15‐item Geriatric Depression Scale (GDS).ResultOf participants from families with a known pathogenic genetic mutation, 47% received genetic disclosure. Of the asymptomatic subset (n=386), 36% know their mutation status. Of these asymptomatic learners, 46% received disclosure through the study, and the remainder learned their genetic status prior to study enrollment. None of the analyzed demographic or psychosocial factors (i.e., sex, age, education, having children) differed between learners and non‐learners (p’s > 0.05). In the longitudinal analysis of asymptomatic participants, learners showed a pre‐ to post‐increase of 0.31 GDS points/year (95%CI: ‐0.08, 0.69, p = 0.12), whereas non‐learners showed a slight decline (‐0.15 points/year, 95%CI: ‐0.36, 0.06, p = 0.16). This difference between slopes was statistically significant (0.46, 95%CI: 0.02, 0.89, p=0.04) but represents a small clinical effect. In asymptomatic learners, slopes did not differ based on mutation status (0.28, 95%CI: ‐0.66, 1.20, p=0.55). Conclusions were based on the estimates and full range of confidence intervals.ConclusionThe majority of asymptomatic research participants do not know their genetic status, which will be a consideration for clinical trials that require disclosure. No considered demographic factors were strongly associated with the decision to receive disclosure. The findings suggest that disclosure in asymptomatic participants has minimal impact on depressive symptoms regardless of genetic results.
Recommended Musculoskeletal and Sports Ultrasound Terminology: A Delphi‐Based Consensus Statement
Hall, Mederic M. , Allen, Georgina , Allison, Sandra J. , Craig, Joseph G. , DeAngelis, Joseph P. , Delzell, Patricia B. , Finnoff, Jonathan T. , Gupta, Atul , Hoffman, Douglas F. , Nazarian, Levon N. , Onishi, Kentaro , Ray, Jeremiah W. , Smith, Jay , Tagliafico, Alberto , Allen, Georgina M , Allison, Sandra , Craig, Joseph , Frank, Rachel M , Gupta, Atul , Hoffman, Douglas F , Jacobson, Jon A , Narouze, Samer , Nazarian, Levon N , Onishi, Kentaro , Ray, Jeremiah W , Sconfienza, Luca M , Smith, Jay , Tagliafico, Alberto , Finnoff, Jonathan T , Jacobson, Jon A. , Narouze, Samer

Mayo Clinic

Journal of Ultrasound in Medicine | February 1, 2022 | Volume: 41 | Issue: 10 | Pages: 2395-2412

10.1002/jum.15947 | PMID 35103998 Get It

Objectives The current lack of agreement regarding standardized terminology in musculoskeletal and sports ultrasound presents challenges in education, clinical practice, and research. This consensus was developed to provide a reference to improve clarity and consistency in communication. Methods A multidisciplinary expert panel was convened consisting of 18 members representing multiple specialty societies identified as key stakeholders in musculoskeletal and sports ultrasound. A Delphi process was used to reach consensus which was defined as group level agreement >80%. Results Content was organized into seven general topics including: 1) General Definitions, 2) Equipment and Transducer Manipulation, 3) Anatomic and Descriptive Terminology, 4) Pathology, 5) Procedural Terminology, 6) Image Labeling, and 7) Documentation. Terms and definitions which reached consensus agreement are presented herein. Conclusions The historic use of multiple similar terms in the absence of precise definitions has led to confusion when conveying information between colleagues, patients, and third‐party payers. This multidisciplinary expert consensus addresses multiple areas of variability in diagnostic ultrasound imaging and ultrasound‐guided procedures related to musculoskeletal and sports medicine.
A prospective observational study to determine the feasibility of tumor response assessment by circulating tumor DNA (ctDNA) in patients with locally advanced rectal cancer (LARC) undergoing total neoadjuvant therapy (TNT).
Chakrabarti, Sakti , McKenna, Edward, Oxencis, Carolyn, Peterson, Carrie Y. , Hall, William A. , Ridolfi, Timothy J. , Miller, James A. , Banerjee, Anjishnu , Chakrabarti, Sakti , LUDWIG, KIRK A. , Erickson, Bradley A. , Thomas, James P.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: TPS234-TPS234

10.1200/jco.2022.40.4_suppl.tps234 Get It

TPS234 Background: Total neoadjuvant therapy (TNT) followed by total mesorectal excision (TME) is one of the standard treatment options for patients with locally advanced rectal cancer (LARC). A commonly employed TNT protocol consists of 8 biweekly cycles of oxaliplatin-based chemotherapy (CT) followed by radiation concurrent with fluoropyrimidine-based chemotherapy (CRT) for about 6 weeks. During the TNT, patients undergo tumor response assessments periodically with standard modalities (SM) consisting of pelvic magnetic resonance imaging (MRI) and proctoscopic/endoscopic examination. The objective of the current protocol is to evaluate the feasibility of tumor response assessment by ctDNA in patients with LARC undergoing TNT. The present feasibility study is designed to collect preliminary data to evaluate if a subsequent larger validation study is justified. If ctDNA-based response assessment is validated, ctDNA can potentially replace at least some components of the SM (for example, MRI) as tumor response assessment by SM is often time-consuming, expensive, and poses logistical challenges. Methods: Patients with LARC undergoing TNT will be enrolled. After obtaining informed consent, venous blood samples will be obtained for ctDNA level measurements at the following time points: baseline (within 1 week before the CT begins), after 4 cycles of CT within +/- 5 days of the MRI study, after 8 cycles of CT within +/- 5 days of the MRI study, and 1 to 14 days before TME. ctDNA levels will be measured by a commercially available ctDNA assay (Signatera by Natera), and ctDNA response is defined as >90% drop in the ctDNA level after treatment compared to the baseline level. Tumor response will be evaluated after 4 and 8 cycles of CT by SM. Primary endpoint: correlation between the response rate (RR) assessed by ctDNA and by SM after 4 cycles of CT. Secondary endpoints: 1) correlation between the RR assessed by ctDNA and by SM after 8 cycles of CT, and 2) correlation between the ctDNA defined RR and the complete pathological response (pCR) rate. The trial will enroll 30 patients. To evaluate the primary endpoint, differences in ctDNA levels between the baseline and 4-cycles post-CT will be computed. The differences will then be expressed as a proportion of each patient’s baseline level, D. This relative change, D, will be compared between the responder and non-responder groups using a two-sample Welch’s t-test. Similar methods will be applied for the secondary endpoints. All analyses will use the nominal type I error level of 0.05 and two-sided tests. Clinical trial information: NCT04670588.
Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.
Mehdi, Maahum , Annunzio, Kaitlin , Taylor, Bradley , Shreenivas, Aditya , Chakrabarti, Sakti , Thomas, James P. , Christians, Kathleen K. , Evans, Douglas B. , Hall, William A. , George, Ben , Chakrabarti, Sakti , Taylor, Bradley , Szabó, Anikó , Tsai, Susan , Clarke, Callisia N. , Erickson, Bradley A. , Thapa, Bicky , Ahmed, Gulrayz , Kamgar, Mandana

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 596-596

10.1200/jco.2022.40.4_suppl.596 Get It

596 Background: Genomic alterations (GA) that drive cancer development and predict therapeutic response remain elusive in patients (pts) with KRAS WT PDAC. We interrogated our institutional database to identify actionable GAs in pts with metastatic, KRAS WT PDAC and analyzed the therapeutic impact of matched TT. Methods: We reviewed electronic medical records of KRAS WT PDAC pts (n=24) who underwent comprehensive genomic profiling (CGP) utilizing Foundation One CDx (25.0%) or Tempus (75.0%) between 2015-2021. Duration of response (DOR) was calculated from date of treatment (Tx) initiation to Tx discontinuation. Overall survival (OS) was measured from the date of the diagnosis (Dx) of advanced disease (AD) to death or last follow-up. OS was estimated using the Kaplan-Meier method, with at-risk periods left-truncated at the time of CGP. The effect of covariates on survival was evaluated using Cox proportional hazards regression. Results: Of the 24 KRAS WT pts, 14 (58%) had AD: 8 (57%) pts had metastatic disease at or shortly after Dx, 6 (43%) pts developed metachronous recurrence. Median age at Dx for pts with AD was 65, and 57% were female. Seven of 14 pts with AD (50%) had highly actionable GA (HAGA), (Table). Pts with HAGA demonstrated durable responses to TT (Table) with manageable toxicities. Pts with HAGA had a median OS of 28 mo compared to 5.9 mo for those without (Hazard Ratio = 0.47, p = 0.33). Conclusions: The sustained therapeutic benefit noted with TT matched to HAGA in pts with KRAS WT PDAC underscores the need for systematic interrogation of the somatic genome in PDAC pts. Optimal sequencing of cytotoxic therapy with TT and its impact on modulating clonal selection pressure in pts with KRAS WT PDAC merits prospective evaluation.[Table: see text]
Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.
Shreenivas, Aditya , George, Ben , Puckett, Lindsay , Chakrabarti, Sakti , Straza, Michael , Hall, William A. , Loy, Veronica , Rilling, William S., Hong, Johnny C. , Gamblin, T. Clark , Smolock, Amanda R. , Christians, Kathleen K. , Dougherty, Kali, Durazo, Francisco , Chakrabarti, Sakti , Thomas, James P. , Awan, Musaddiq J. , Kamgar, Mandana , Tsai, Susan , Danziger, Natalie , Ross, Jeffrey S.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 474-474

10.1200/jco.2022.40.4_suppl.474 Get It

474 Background: FLO is a rare variant of liver cancer that disproportionately affects young adults and is frequently progressive and fatal as it is often detected in a clinically advanced stage. It is seldom associated with cirrhosis of liver, viral hepatitis or other risk factors associated with conventional HCC. Treatment options are largely limited to surgical resection, and there is dearth of effective targeted therapies for FLO. Methods: Comprehensive genomic profiling (CGP) was performed using the Foundation Medicine Inc. (FMI) data base on 63 FLO and 1,793 HCC clinically advanced cases between 6/2013-12/2020 using a hybrid capture-based assay of up to 324 genes a to detect genomic alterations (GA), tumor mutational burden (TMB) and microsatellite instability (MSI). PD-L1 expression in tumor cells (Dako 22C3) was measured by IHC and scored using the tumor proportion score (TPS) method. Results: The FLO patients (pts) were significantly younger than HCC pts (median age 20 vs. 64, respectively) and the male preponderance was similar. The HCC group featured significantly more GA/tumor than FLO group (3.74 vs 1.31 p<.0001). In the currently untargetable GA group, CTNNB1, TERT and TP53 GA were significantly more frequent in HCC than FLO. GA in potentially targetable genes were extremely uncommon in both FLO and HCC with HCC featuring slightly more MTOR pathway targets ( PTEN, TSC2, NF1). GA in DNA damage and repair (DDR) pathway including BRCA2 were infrequent in both groups. GA in targetable kinases including EGFR, ERBB2, ALK, RET and PIK3CA were extremely uncommon in both groups. GA associated with intrahepatic cholangiocarcinoma (IDH1, FGFR2) were extremely uncommon in these tumors. Although the mean TMB was significantly higher in HCC than FLO, overall TMB was low with very few cases having TMB > 10 mutations/Mb. PD-L1 expression was relatively low in both groups. GA in genes associated with immune checkpoint inhibitors (ICPI) drug response like PBRM1, CD274, MDM2, STK11 were rarely identified in both groups. Additional details are illustrated in the table. Conclusions: Comparison of CGP of FLO with HCC illustrates the multifarious nature of these cancers. In HCC, there is a high prevalence of GA in TERT, CTNNB1 and TP53. CGP identified certain targetable GA in the MTOR and DDR pathways and TMB was higher in HCC. These findings warrant further evaluation of clinically advanced FLO and HCC pts by CGP to identify possible targetable genomic pathways. [Table: see text]
Survival outcome and treatment response of patients with young-onset locally advanced rectal cancer (YO-LARC) receiving total neoadjuvant therapy (TNT).
McKenna, Edward, Oxencis, Carolyn, Parish, Marie, Eastwood, Daniel , Miller, James A. , Shreenivas, Aditya , George, Ben , Hall, William A. , Chakrabarti, Sakti , Chakrabarti, Sakti , Kamgar, Mandana , Erickson, Bradley A. , LUDWIG, KIRK A. , Szabó, Anikó , Thomas, James P.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 44-44

10.1200/jco.2022.40.4_suppl.044 Get It

44 Background: Despite an alarming rise in incidence, data on survival outcome and treatment response of young-onset (age < 50 years) locally advanced rectal cancer (YO-LARC) patients receiving total neoadjuvant therapy (TNT) are sparse. We retrospectively compared the outcome between YO-LARC and later-onset (aged 50 years or older) LARC (LO-LARC) patients treated with TNT. Methods: After the institutional review board approval, electronic medical records of the LARC (T3/T4 or node-positive) patients treated with TNT at a tertiary care cancer center between January 1, 2015, and June 30, 2020, were reviewed for data collection. TNT consisted of systemic chemotherapy with oxaliplatin-based regimens for 16 weeks followed by long-course radiation with concurrent capecitabine or 5-fluorouracil (CRT). Patients receiving only preoperative CRT were excluded. Most patients underwent surgical resection following the TNT. Non-operative management was offered to patients if TNT resulted in clinical complete response (cCR). The following comparisons between the YO-LARC and the LO-LARC patients were performed: patient characteristics, pathological complete response (pCR) rate, combined pCR + cCR rate, disease-free survival (DFS), and overall survival (OS). Results: Of 72 patients included in the analysis, 44(61%) were male, 49 (68%) were Caucasian, and 62 (86%) had clinical stage III disease. The study included 26 (36%) patients with YO-LARC (median age, 43 years) and 46 (64%) patients with LO-LARC (median age, 64 years). The comparison of patient characteristics that included gender, clinical stage, baseline carcinoembryonic antigen level, the distance of the tumor from the anal verge, presence of high-risk features, and histologic grade did not differ significantly between the groups. There were no statistically significant differences in pCR and combined pCR+cCR rates (p = 0.16) between the groups: YO-LARC, 12 % (3/26) and 15 % (4/26), respectively; LO-LARC, 22% (10/46) and 30% (14/46), respectively. Either group did not reach median DFS and OS after a median follow-up of 38 months for survivors. The estimated 5-year OS rates in patients with YO-LARC and LO-LARC were 86 % (95% confidence interval [CI], 69% to 100%) and 84% (95% CI, 68% to 100%), respectively (p = 0.92). The estimated 3-year DFS rates in patients with YO-LARC and LO-LARC were 67 % (95% CI, 50% to 89%) and 83% (95% CI, 72% to 95%), respectively (p = 0.19). Conclusions: The current retrospective analysis did not demonstrate significant differences in the pCR rates, combined pCR +cCR rates, DFS, or OS between the YO-LARC and LO-LARC patients treated with TNT.
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Durani, Urshila , Major, Ajay , Velázquez, Ana I. , May, Jori E. , Nelson, Marquita , Zheng, Ze , Hall, Anurekha G. , Alam, Sara Taveras , Reynolds, Robby , Thompson, John Colton, Kumbamu, Ashok , Das, Devika , Murphy, Martina, Henry, Elizabeth , Lee, Alfred Ian , Marshall, Ariela L. , Weeks, Lachelle D. , May, Jori , Wun, Ted , Weeks, Lachelle Dawn , Marshall, Ariela , Major, Ajay , Velazquez, Ana I , Durani, Urshila , Wun, Ted

Mayo Clinic

JCO Oncology Practice | January 6, 2022 | Volume: 18 | Issue: 4 | Pages: e586-e599

10.1200/op.21.00630 | PMID 34990292 Get It

PURPOSE: Graduate medical and research training has drastically changed during the COVID-19 pandemic, with widespread implementation of virtual learning, redeployment from core rotations to the care of patients with COVID-19, and significant emotional and physical stressors. The specific experience of hematology-oncology (HO) fellows during the COVID-19 pandemic is not known. METHODS: We conducted a mixed-methods study using a survey of Likert-style and open-ended questions to assess the training experience and well-being of HO fellows, including both clinical and postdoctoral trainee members of the American Society of Hematology and ASCO. RESULTS: A total of 2,306 surveys were distributed by e-mail; 548 (23.8%) fellows completed the survey. Nearly 40% of fellows felt that they had not received adequate mental health support during the pandemic, and 22% reported new symptoms of burnout. Pre-existing burnout before the pandemic, COVID-19–related clinical work, and working in a primary research or nonclinical setting were associated with increased burnout on multivariable logistic regression. Qualitative thematic analysis of open-ended responses revealed significant concerns about employment after training completion, perceived variable quality of virtual education and board preparation, loss of clinical opportunities to prepare for independent clinical practice, inadequate grant funding opportunities in part because of shifting research priorities, variable productivity, and mental health or stress during the pandemic. CONCLUSION: HO fellows have been profoundly affected by the pandemic, and our data illustrate multiple avenues for fellowship programs and national organizations to support both clinical and postdoctoral trainees.
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
Weber, Christopher J., Carrillo, María C. , Jagust, William J. , Shaw, Leslie M. , Trojanowski, John Q. , Saykin, Andrew J. , Sur, Cyrille, Méndez, Patricio Chrem, Li, Kuncheng , Iwatsubo, Takeshi , Perrin, Richard J. , Morris, John C. , Healan, Amanda M.B., Weiner, Michael W. , Saykin, Andrew J , Morris, John C , Jack, Clifford R. , Beckett, Laurel , Rao, Naren Prahalada , Black, Sandra E. , Chang, Chiung‐Chih , Sosa, Ana Luisa , Rowe, Christopher Cleon , Hall, Stephen E.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | December 31, 2021 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/trc2.12226 | PMID 35005206 Get It

Abstract The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4.
Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19
Gillet, A.S. , Zu, Yuanhao, Brown, Margo, Pham, Thaidan , Yoshida, Yilin , Douglas, Ivor S. , Moore, Mathew, Tea, Kevin, Wetherbie, Andrew, Stevens, Rachael, Lefante, John J., Shaffer, Jeffrey G. , Armaignac, Donna Lee , Belden, Katherine A. , Kaufman, Margit, Heavner, Smith F. , Danesh, Valerie , Hill, Catherine A. St., Boman, Karen , Bansal, Vikas , Kumar, Vishakha K. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Mesland, Jean-Baptiste , Henin, Pierre , Petre, Hélène, Buelens, Isabelle, Gérard, A , Granado, Rolando Claure-Del, Vega-Terraza, Esdenka, Iturricha-Cáceres, Maria F., Garza, Rubén , Chan, Victoria , Gavidia, Oscar Y., Pachon, Felipe, Tawheed, Ahmed , Pineda, Estela , Guillen, Gabina María Reyes, Soto, Helin Archaga, Lizardo, Ana Karen Vallecillo, Segu, Smitha, Chakraborty, T., Joyce, Epcebha, Kasumalla, Phani Sreeharsha, Vadgaonkar, Girish, Ediga, Rekha, Basety, Shilpa, Dammareddy, Shwetha, Raju, Umamaheswara, Manduva, Janaki, Kolakani, Naresh, Sripathi, Shreeja , Chaitanya, Sheetal, Parameswaran, Sreejith , Parthiban, Magesh, Menu, P., Daga, Mardul Kumar, Agarwal, Munisha , Rohtagi, Ishan, Papani, Sridhar, Kamuram, Mahesh, Agrawal, Kamlesh Kumar , Baghel, Vijendra, Patel, K, Mohan, Surapaneni Krishna, Jyothisree, Ekambaram, Dalili, Nooshin , Nafa, Mohsen, Matsuda, Wataru , Suzuki, Reina , Horikita, Sho, Kodate, Akira, Takahashi, Yuki , Moriki, Koyo, Iwasaki, Yudai , Rodríguez‐Gutiérrez, René , Gonzale, Jose Gerardo, Salcido‐Montenegro, Alejandro , Hassan-Hanga, Fatimah , Gezawa, Abubakar Shehu, Kabir, Halima , Amole, Taiwo Gboluwaga , Haliru, Dalha Gwarzo, Ibrahim, Abdullahi S., Asghar, Muhammad Sohaib , Syed, Mashaal , Naqvi, Syed Anosh Ali, Заболотских, И. Б. , Alamoudi, Razan K., Alsharif, Hassan, Almazwaghi, Sarah A., Elsakran, Mohammed S., Aid, M., Darwich, Mouaz A., Hagag, Omnia M., Ali, Salah A., Rocacorba, Alona, Supeña, Kathrine, Juane, Efren Ray, Medina, Jenalyn, Baduria, Jowany, Amer, Marwa , Dahhan, Talal, Kseibi, Eiad, Butt, Abid Shahzad, Khurshid, Syed Moazzum, Rabee, Muath, Abujazar, Mohammed, Alghunaim, Razan K, Abualkhair, Maal, AlFirm, Abeer Turki, Alarifi, Mohammed I, Macarambon, Jara Mia, Bukhari, Ahmad Abdullah, Albahrani, Hussian A, Aldossary, Kaltham M., Zoran, Marija Zdravkovic, Popadic, Viseslaz, Bojicic, Jovana, Predrag, Stevanović, Stojakov, Dejan , Ignjatovic, Duska K., Bojicic, Suzana C, Bobos, Mariana M, Nenadić, Irina , Zaric, Milica S., Djuric, Marko , Djukic, Vladimir R., Teruel, Santiago, Martin, Belen C., Bilgin, Huseyin, Dodd, Kenneth W. , Goodmanson, Nicholas, Hesse, Kathleen, Bird, P. H., Weinert, Chauncey, Schoenrade, Nathan, Altaher, Abdulrahman, Mayar, Esmael, Aronson, Matthew, Cooper, Tyler, Logan, Monica, Miner, Brianna, Papo, Gisele, Siegal, Eric M., Runningen, Phyllis, Patel, Love , Melamed, Roman , Tierney, David M. , Raj, Vino S., Mazumder, Narayana, Hill, Catherine St., Kirkland, Lisa L., Schmitz, Nova J., Sigman, Alena, Hall, Joan, Raval, Abhijit, Franks, Andrea S. , Jarvis, Jennifer M., Kharbanda, Anmol, Jhajhria, Sunil, Fyffe, Zachary, Capizzi, Stephen A., Alicie, Bethany, Green, Martha, Corckarell, Lori, Drennan, A. M., Dubuque, Kathleen, Fambrough, Tonya, Gasaway, Nikole, Krantz, Briana, Nebi, Peiman, Orga, Jan, Serfass, Margaret, Simion, Alina, Warren, Kimberly R., Wheeler, Cassie, Woolman, C. J., Christie, Amy B. , Adiga, Rajani, Moyer, A, Verghese, George M., Forehand, Chirsty C, Sabov, Moldovan, Zaidi, Fatema, Tissavirasingham, Fiona, Malipeddi, Dhatri , Campbell, Beth Salvagio , Wilson, Cathleen, Rivers, Patrick , Brinks, Jonathan, Mongoh, Mokenge Ndiva, Gilson, Boris, Armaignac, Donaa Lee, Parris, Don, Zuniga, Maria Pilar, Vargas, Ilea, Boronat, Viviana, Hutton, Anneka, Kaur, Navneet , Neupane, Prashank, Sadule-Rios, Nohemi, Rojas, Lourdes M. , Neupane, Aashish, Rivera, Priscilla, Carlos, Carlos Valle, Amin, Mahesh, Schelle, Mary E, Steadham, Amanda, McBride, Cameron , Abraham, Jocelyn, Richards, Katherine , Collins, Keegan, Antony, Preethi, Dubrocq, Gueorgui , Davis, Amber, Hammers, Marissa J, McGahey, Ill M, Farris, Amanda C., Priest, Elisa L. , Korsmo, Robyn, Fares, Lorie, Skiles, Kathy, Shor, Susan M, Burns, Kenya, Flores, Melody, Newman, Lindsay, Wilk, Debora A., Ettlinger, Jason, Bomar, Jaccallene, Darji, Himani, Arroliga, Alejandro C. , Dowell, Corrie A., Gonzales, Gabriela “ Hope”, Garcia, Michael A. , Colona, Mia R., Kibbelaar, Zoé A. , Leong, Michael S. , Wallman, Daniel , Soni, Kanupriya , Maccarone, Jennifer , Gilman, Joshua, Devis, Ycar, Chung, Joseph, Paracha, Munizay , Lumelsky, David , DiLorenzo, Madeline A. , Abdurrahman, Najla, Johnson, Shelsey W. , Hersh, Maj Andrew M., Wachs, Stephanie, Swigger, Brittany S., Sattler, L, Moulton, Michael N., Zammit, Kimberly, Loeffler, William, Tirupathi, Raghavendra , Tang, Alymer, Safi, Arshad M., Green, Cindy, Newell, J.D., Ramani, Naga, Ganti, Bhavani Harika, Ihle, R , Davis, Elaine , Martin, Shelda A, Sayed, Imran A., Strom, Larisa, Lee, Giyoung , Burnett, Ryan H., Sydney, Guy I. , Traynor, Danielle M., White, Joshua, Khan, Aftab, Dhahwal, Rahul, Ahmed, Farzin, Deonarine, Chrispoter, Jones, Ashley, Shaikh, Mohammad Ali, Preston, David A. , Chin, Jeanette, Duggal, Abhijit, Rajendram, Prabalini , Mehkri, Omar , Biehl, Michelle, Houltham, Stuart, Kind, Alexander, Ashok, Kiran, Poynter, Bryan, Beukemann, Mary, Rice, Richard, Gole, Susan, Shaner, Valerie , Conjeevaram, Adarsh, Ferrari, Michlelle, Alappan, Narendrakumar, Minear, Steven , Hernández-Montfort, Jaime , Nasim, Syed Sohaib, Sunderkrishnan, Ravi, Sahoo, Debasis , Milligan, Patrick S., Koglin, Joy M., Gibson, Regina, Johnson, Lana, Preston, Felicia, Scott, Crimson, Nungester, Bethany, Byrne, Dana , Grant, Katie, Doktar, Katherine L, Porto, Maura C, Kaplan, Olgo, Schonewald, Brian, Woodford, Ashley L., Tsai, Alan , Reid, Savina, Bhowmick, Kuntal, Daneshpooy, Saba , Mowdawalla, Cyrus , Dave, Trishna Akshay, Crudeli, Wilhemina Kennedy Connor, Ferry, Chirstopher, Nguyen, Long , Modi, Sneha, Padala, Niharika, Patel, Pavan Jitendra, Lin, Belle, Qiuyun, Jamie, Liu, Fan Mandi, Kota, Rasagna, Banerjee, Annesha , Daugherty, Steven K., Atkinson, Sam, Shrimpton, Kelly, Ontai, Sidney , Contreras, Brian, Obinwanko, Uzoma, Amamasi, Nneka, Sharafi, Amir, Lee, Sarah , Esber, Zahia , Jinjvadia, Chetna, Krishnamoorthy, Vijay , Kraft, Bryan , Pulsipher, Aaron, Friedman, Eugene, Mehta, Sachin , Kaufman, Margit, Lobel, G, Gandhi, Nisha, AbdelAty, Amr M. , Shaji, Elizabeth, Lim, Kiana, Marte, Juan M., Sosa, Dani Ashley, Benjenk, Ivy , Prasanna, Nivedita, Perkins, Nicholas , Roth, Prera J, Litwin, Alain H. , Pariyadath, Ananda, Moschella, Phillip , Llano, Trayson, Waller, Christine, Kallies, Kara J. , Thorsen, Jonean , Fitzsimmons, Alec , Olsen, H. L., Smalls, Normal, Davis, S., Jovic, Valentina, Masuda, M, Hayes, Amanda, Nault, Katharine, Snow, William G., Liptak, Riley, Durant, Hannah, Pendleton, Valerie, Nanavati, Alay, Mrozowsk, Risa, Doubleday, Erica, Liu, Yuk Min, Zavala, Sarah , Shim, Esther, Reilkoff, Ronald A., Eichen, Sarah, Goertzen, Lexie, Rajala, Scott, Feussom, Ghislaine, Junia, Christine, Lichtenberg, Robert, Sidhu, Hasrat, Espinoza, Diana , Rodrigues, Shelden , Zabala, Marai Jose, Susheela, Ammu , Hatharaliyadda, Buddhi, Rameshkumar, Naveen, Kasireddy, Amulya, Beltran, Lisseth, Chaugule, Akshata, Patil, Namrata, Patil, Ruhi, Cartin‐Ceba, Rodrigo , Sen, Ayan , Talaei, Fahimeh , Domecq, Juan Pablo , Gajic, Ognjen, Sharma, Mayank , Qamar, Shahraz , Morales, Diana J. Valencia , Nou, Abigail T. La, Bogojevic, Marija , Sanghavi, Devang , Franco, Pablo Morno, Ganaphadithan, Karthik, Saunders, Hollie , Fleissner, Zachary, Mateus, Alejandra Yu Lee, Kaur, Nirmaljot , Giri, Abhisekh, Hasan, Mohammed Mustafa, Donepudi, Ashrita , Khan, Syed Anjum , Jain, Nitesh , Koritala, Thoyaja , Nanchal, Rahul , Peterson, Jennifer , Yamanaka, Travis, Barreras, Nicholas A., Markos, Michael, Fareeduddin, Anita, Mehta, Rohan, Venkata, Chakradhar , Engemann, Miriam, Mantese, Annamarie, Tarabichi, Yasir , Wang, Christine, Kotekal, Dhatri, Bierwirth, Adriana C. Briceno, Orellana, Gabriela, Catalasan, Gerardo , Ahmed, Shohana, Salinas, Ivania, Nogal, Genesis Del, Tejada, Ángel Morales-Martínez de, Chen, Jen‐Ting , Hope, Aluko A. , Tsagaris, Zoe, Ruen, Elise, Hambardzumyan, Aram, Siddiqi, Nasar A, Jurado, Lesly, Tincher, Lindsey, Brown, Carolyn , Aulakh, Bhagat , Bandy, Jennifer A., Kreps, Lisa M., Bollinger, Dwan R, Stienecker, Roger Scott , Melendez, Andre G, Brunner, Tressa A., Budzon, Sue M., Heffernan, J., Souder, Janelle M., Miller, Tracy L., Maisonneuve, A., Redfern, Roberta E. , Shoemaker, Jessica, Micham, Jennifer, Kenney, Lynn, Naimy, Gabriela, Pulver, Kerry P J, Yehle, Jennifer, Weeks, Alicia, Inman, T., Delmonaco, Brain L, Franklin, Anthony , Heath, Mitchell, Vilella, Antonia L. , Kutner, Sara B., Clark, Kacie , Anderson, Harry L, Rajkumar, Dixy, Abunayla, Ali, Heiter, Jerrilyn, Zaren, Howard A. , Smith, Stephanie J., Lewis, Grant C., Seames, Lauren, Farlow, Cheryl, Miller, Judy, Broadstreet, Gloria, Martinez, Anthony , Allison, Micheal, Mittal, Aniket, Ruíz, Rafael Azuar , Skaanland, Aleta, Patel, Umang, Hodge, Jordesha, Patel, Krunal Kumar, Dalal, Shivani , Kavani, Himanshu , Joseph, Sam W. , Bernstein, Michael, Goff, Ian K., Naftilan, Matthew, Mathew, Amal , Williams, Debora, Murdock, Sue, Ducey, Maryanne, Nelson, Kerianne, Mitchel, James, Cox, Sylvan, Amzuta, Ioana, Shah, Amish , Modi, Ritu, Al-Khalisy, Hassan, Masuta, Pradeep, Schafer, Melissa , Wratney, Angela, Carter, K., Olmos, M. A. Martinez, Parker, Brittany M, Quintanilla, Julio, Craig, Tara A, Clough, B., Jameson, J, Jones, Tacy L, Ayers, Shonda C., Harrell, Amy B., Brown, Brent R., Darby, Caleb, Page, Kristy, Brown, Amanda, McAbee, Jessie, Baram, Michael , Weber, Devin , DePaola, Rosalie, Xia, Yuwei , Carter, Hudson, Tolley, A. E., Ferranti, Mary, Steele, Mark P., Kemble, Laurie, Sethi, Joshua, Han, Chung Cheng, Pagliaro, Jaclyn , Husian, Abdurrahman, Zawaydeh, Qais , Sines, B. , Markotić, Dragana, Bošnjak, Ivana, Nicholson, Susannah E. , Jonas, Rachelle B., Dement, AnnaRose E, Tang, William , DeRose, Mark, Villarreal, Robert E, Dy, Rajany , Lardino, Alfredo, Sharma, Jill H., Czieki, Richard, Christopher, Julia, Lacey, Ryan, Mashina, Marwan , Patel, Kushal, Gomaa, Dina , Goodman, Micahel, Spuzzillo, Anthony , Shinn, John O., Baslanti, Tezcan Ozrazgat, Omalay, George, Hashemighouchani, Haleh , Cupka, Julie S , Galet, Colette , Hubbard, Janice, Nazir, Usman, Rampon, Garrett , Riggle, Jake, Dismag, Nathan, Lenhardt, Rainer, Cavallazzi, Rodrigo , Jerde, Ann, Black, Alexa, Polidori, A., Griffey, Haily, Winkler, J., Brenzel, Thomas, Alvarez, Rodger A, Alarocon-Calderon, Amarilys, Sosa, Marie Anne , Mahabir, Sunita, Patel, Mausam , Parker, Pauline, Admon, Andre, Hanna, Sinan, Pliakas, Maria , Wolski, Ann, Cirino, Jennifer, Geiger, Grant , Njai, Abdoulie , Saad, Baraa M., Chuan, Byron, Rawal, Sagar L, Piracha, Manal, Levin, Nicholas M. , Suslavich, Kayte , Tsolinas, Rachel , Fica, Zachary , Skidmore, Chloe R., Stapleton, Renee D., Dixon, Anne E. , Johnson, Olivia, Ardren, Sara S., Burns, Stephanie, Raymond, Anna, Gonyaw, Erika, Hodgdon, Kevin , Houseger, Chole, Lin, Benjamin R. , McQuesten, Karen, Grimm, Heidi Pecott-, Sweet, Julie, Ventrone, Sebastian, Khandelwal, Nita , Lovelace-Macon, Lara, Garimella, Navya, Dow, Denisse Bazan, Rahman, Rania Abdul, Mulrow, Mary, Wilfong, Erin M. , Vela, Kelsi, Harris, Lynne, Cusson, Bruce, Fowler, Jacob , VanEenenaam, David P., Mckinney, Glen , Udoh, Imoh, Johnson, Kathleen N. , Michelson, Andrew P. , Haulf, Sara S, Lynch, Lauren, Steinbery, Aaron, Braus, Nicholas, Pattan, Vishwanath , Papke, J, Jimada, Ismail, Mhid, Nida, Chakola, Samuel, Sheth, Kevin N., Ammar, Abdalla , Lopez, Victor Torres , Khosla, Akhil , Gautam, Samir C. , Lee‐Mateus, Alejandra Yu , Bansal, Vikas , Yu Lee-Mateus, Alejandra , Kaur, Nirmaljot , Asghar, Muhammad S , Redfern, Roberta E , Denson, Joshua L. , Mauvais‐Jarvis, Franck , Cheruku, Sreekanth , Deo, Neha , Walkey, Allan J. , Kashyap, Rahul , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Clevenbergh, Philippe Albert , Granado, Rolando Claure‐Del , Mercado, Jose A, Garza, Ruben, Chu, Eric, Chan, Victoria, El‐Kassas, Mohamed , Chakraborty, Tuhin, Cherian, Anusha , Menu, Priya A, Sanui, Masamitsu , Itagaki, Yuki , Shiga, Takuya , Camacho-Ortíz, Adrián , Galadanci, Hadiza , Syed, Mashaal, Musaeva, Tatiana Sergeevna , Bawazeer, Mohammed Abdullah , Alghunaim, Razan K, Almazyad, Mohammed , Asfina, Kazi Nur , Klašnja, Slobodan , Kovačević, Bojan , Teruel, Santiago Y, Sili, Uluhan , Ay, Pınar , Bird, Paige, Schoenrade, Nathan, Hall, Joan, Franks, Andrea, Drennan, Amelia, Warren, Kimberly, Ashley, Dennis W. , Sikora, Andrea , Bruning, Rebecca, Jones, Timothy W, Mosier, Jarrod , Lutrick, Karen , Vincent, Gregory, Howard, Christopher M. , Garner, Orlando , Mathew, Sindhu, Dubrocq, Gueorgui , Waikar, Sushrut S. , Leong, Michael, McGrath, Patrick J, Chilbert, Maya R. , Green, Cindy, Ihle, Rayan E, Martin, Shelda A., Gist, Katja M. , Chiotos, Kathleen , Blatz, Allison M. , Surani, Salim , White, Joshua, Khan, Aftab, Preston, David, Vachharajani, Vidula , Dugar, Siddharth , Sacha, Gretchen , Kind, Alexander, Gole, Susan, Gupta, Sandeep , Schorr, Christa , Siegler, James E. , Bartz, Raquel R. , Mehta, Sachin, Kaufman, Margit, Abdelaty, Amr, Yamane, David , Pariyadath, Anand, Olsen, Haley, Smith, Michael A. , Snow, William, Heneghan, Julia A. , Tang, Ben, Goyes, Daniela , Maldonado, Génessis , Khan, Hassan, Gajic, Ognjen , Tekin, Aysun , Lal, Amos , O’Horo, John C. , Singh, Romil , Nou, Abigail La, Zec, Simon , Guru, Pramod , Garcia, Juan, Yarrarapu, Siva Naga S. , Bergl, Paul A. , Peterson, Jennifer L, Perzynski, Adam T. , Wang, Christine, Matute, Carlos , Hamdan, Ahmad, Tejada, Angel, Tripathi, Sandeep , Inman, Terra, Moore, Danielle, Anderson, Harry L, Miller, Judy, Ruiz, Rafael, Ross, Robert, Joseph, Sam, Block, Jason, O’Brien, Connor , Carter, Kristina L, Olmos, Michael, Gupta, Neha , Darby, Caleb, Tolley, Aaron, Malhotra, Atul , Bice, Thomas J. , Bosnjak, Ivana, Vail, Emily A. , Tang, William, Villarreal, Roberto E., Patel, Kushal, Wakefield, Devin, Bihorac, Azra , Ruppert, Matthew M. , McGonagill, Patrick W. , Wang, David , Allan, Lauren , Badheka, Aditya V. , Chegondi, Madhuradhar , Akça, Ozan , Polidori, Allison, Winkler, Justin, Chanderraj, Rishi , Dandachi, Dima , Regunath, Hariharan , Camazine, Maraya , Saad, Baraa, Shah, Faraaz A , Tonna, Joseph E. , Lin, Benjamin, Pecott-Grimm, Heidi, West, T. Eoin , Caldwell, Ellen , Akhter, Murtaza , Khanna, Ashish , Lyons, Patrick G. , Lynch, Lauren M, Nguyen, Nguyet Minh , Papke, Jessica, Ammar, Mahmoud A , Dela Cruz, Charles S

Mayo Clinic

JAMA Network Open | December 22, 2021 | Volume: 4 | Issue: 12 | Pages: e2140568

10.1001/jamanetworkopen.2021.40568 | PMID 34935924 Get It

121. Evaluation of Multifaceted Antimicrobial Stewardship in Optimizing Antimicrobial Usage in Intraabdominal Infection at a Community Hospital
Pham, Tho H , Huang, Angela , Hall, Scott T. , Huang, Vanthida

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S174-S174

10.1093/ofid/ofab466.323 Get It

Abstract Background Treatment of intraabdominal infections (IAI) commonly involves broad spectrum antimicrobials based on the severity and etiology of infections as well as the underlying medical conditions. However, the overuse of broad-spectrum agents has driven selection for Gram-negative and -positive resistance, as well as collateral consequences such as Clostridioides difficile colitis. We sought to evaluate the utilization of a pharmacy-driven multifaceted antimicrobial stewardship (AMS) intervention to optimize empiric antimicrobial therapy by risk stratification among IAI patients and reduce the number of antibiotic treatment days. Methods This is a single-center case observation study in hospitalized adult IAI patients on antimicrobial therapy from Dec 2019-Feb 2020 compared to patients from Dec 2020-Feb 2021 after initiation of AMS with daily prospective audit and feedback. The composite primary outcome is reduction of antibiotic treatment days and de-escalation from broad spectrum antibiotics (fluoroquinolones, piperacillin/tazobactam, and carbapenems) to cephalosporins. Results We identified 40 patients each in the baseline (pre-AMS group) and post-AMS group via electronic medical record. Baseline characteristics were well-matched between groups. The majority of patients were diagnosed with community-acquired IAIs such as appendicitis, diverticulitis, and cholecystitis. Fluoroquinolone use as empiric therapy was significantly lower in the post-AMS group vs. pre-AMS group (2.5% vs. 25%, p&lt; 0.001), while non-Pseudomonas cephalosporin use was increased (25% post-AMS vs. 0% pre-AMS, p&lt; 0.001). Oral fluoroquinolone use at discharge was significantly decreased in the post-AMS group (p&lt; 0.001). Antibiotic treatment days remained unchanged. There was no statistical difference between the two groups in 30-day mortality, 30-day readmission, relapse, and C. difficile colitis. Conclusion A multifaceted antimicrobial therapy intervention successfully reduced the use of fluoroquinolones in patients with community-acquired IAI during hospitalization and discharge. No differences in mortality, readmission, or relapse rates were observed. Disclosures All Authors: No reported disclosures